The primary outcome is to evaluate the effect of Cynacol on the change in LDL-C levels compared to Metacol after 90 days of supplementation.
The secondary outcomes are to evaluate:
\- the change of TC, non-HDL cholesterol (non-HDL-C), apolipoprotein B (apoB), Tg, HDL-C levels after 90 days of supplementation with Cynacol compared to Metacol. The safety outcome is collection of the adverse events not related, related or possibly related to the study products.
age between 35-70 years
both genders
LDL-C levels between 115 and 190 mg/dl
subjects able to understand the informed consent and sign it before enrollment in the study
personal history of cardiovascular disease or equivalent risk factors
Tg levels ≥ 400 mg/dl
obesity [body mass index (BMI) ≥ 30 kg/m²]
taking hypolipidemic drugs or supplements that affect lipid metabolism